📊 GDRX Key Takeaways
Is GoodRx Holdings, Inc. (GDRX) a Good Investment?
GoodRx exhibits concerning fundamental weakness with flat revenue growth (0.6% YoY), anemic profitability (0.6% net margin), and critically, interest coverage of only 0.5x—meaning operating income fails to cover debt service obligations. While the company maintains adequate liquidity and positive free cash flow, the combination of minimal growth, razor-thin returns (ROE 0.2%), and high leverage relative to profitability creates an unsustainable financial structure.
GoodRx shows solid underlying financial quality through strong free cash flow generation, good liquidity, and a sharp rebound in net income and diluted EPS. However, revenue growth is nearly flat and interest coverage is only moderate, which limits the strength of the fundamental outlook despite improved profitability.
Why Buy GoodRx Holdings, Inc. Stock? GDRX Key Strengths
- Strong cash position of $235.7M provides liquidity buffer and financial flexibility
- Healthy liquidity ratios (1.47x current and quick ratios) reduce near-term solvency risk
- Positive free cash flow generation of $10.7M demonstrates operational cash generation capability
- Strong free cash flow generation with a 20.6% FCF margin
- Healthy balance sheet liquidity with current and quick ratios of 2.61x
- Net income and diluted EPS improved materially year over year
GDRX Stock Risks: GoodRx Holdings, Inc. Investment Risks
- CRITICAL: Interest coverage ratio of 0.5x indicates operating income cannot cover debt service—operationally unsustainable leverage structure
- Revenue growth essentially flat at 0.6% YoY with net margin of only 0.6%—company shows no growth momentum and barely profitable
- Extremely poor capital efficiency with ROE of 0.2% and ROA of 0.1%—shareholder capital is not generating meaningful returns
- High debt burden of $482.4M against minimal profitability creates refinancing and covenant risk if operational performance deteriorates
- Revenue growth of 0.6% suggests limited top-line momentum
- Interest coverage of 3.0x leaves less room if operating performance weakens
- Net margin of 3.8% remains modest relative to the company's cash flow profile
Key Metrics to Watch
- Interest coverage ratio—must move above 1.0x to reach operational sustainability
- Revenue growth rate and net margin trajectory—need to demonstrate acceleration or expansion
- Operating cash flow to interest expense ratio—monitor ability to service debt organically
- Debt reduction and leverage ratio—track progress on deleveraging given weak profitability
- Revenue growth acceleration
- Interest coverage and debt reduction progress
GoodRx Holdings, Inc. (GDRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
GoodRx Holdings, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GDRX Profit Margin, ROE & Profitability Analysis
GDRX vs Technology Sector: How GoodRx Holdings, Inc. Compares
How GoodRx Holdings, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GoodRx Holdings, Inc. Stock Overvalued? GDRX Valuation Analysis 2026
Based on fundamental analysis, GoodRx Holdings, Inc. shows some fundamental concerns relative to the Technology sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GoodRx Holdings, Inc. Balance Sheet: GDRX Debt, Cash & Liquidity
GDRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GoodRx Holdings, Inc.'s revenue has shown modest growth of 7% over the 5-year period. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
GDRX Revenue Growth, EPS Growth & YoY Performance
GDRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $194.0M | $1.2M | $0.00 |
| Q3 2025 | $195.3M | -$1.0M | $0.00 |
| Q2 2025 | $200.6M | -$1.0M | $0.01 |
| Q1 2025 | $197.9M | -$1.0M | $0.00 |
| Q3 2024 | $180.0M | -$1.0M | $0.01 |
| Q2 2024 | $189.7M | -$1.0M | $0.01 |
| Q1 2024 | $184.0M | -$1.0M | $0.00 |
| Q3 2023 | $180.0M | -$1.4M | $0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GoodRx Holdings, Inc. Dividends, Buybacks & Capital Allocation
GDRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GoodRx Holdings, Inc. (CIK: 0001809519)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GDRX
What is the AI rating for GDRX?
GoodRx Holdings, Inc. (GDRX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GDRX's key strengths?
Claude: Strong cash position of $235.7M provides liquidity buffer and financial flexibility. Healthy liquidity ratios (1.47x current and quick ratios) reduce near-term solvency risk. ChatGPT: Strong free cash flow generation with a 20.6% FCF margin. Healthy balance sheet liquidity with current and quick ratios of 2.61x.
What are the risks of investing in GDRX?
Claude: CRITICAL: Interest coverage ratio of 0.5x indicates operating income cannot cover debt service—operationally unsustainable leverage structure. Revenue growth essentially flat at 0.6% YoY with net margin of only 0.6%—company shows no growth momentum and barely profitable. ChatGPT: Revenue growth of 0.6% suggests limited top-line momentum. Interest coverage of 3.0x leaves less room if operating performance weakens.
What is GDRX's revenue and growth?
GoodRx Holdings, Inc. reported revenue of $194.0M.
Does GDRX pay dividends?
GoodRx Holdings, Inc. pays dividends, with $1,346.4M distributed to shareholders in the trailing twelve months.
Where can I find GDRX SEC filings?
Official SEC filings for GoodRx Holdings, Inc. (CIK: 0001809519) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GDRX's EPS?
GoodRx Holdings, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GDRX a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, GoodRx Holdings, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GDRX stock overvalued or undervalued?
Valuation metrics for GDRX: ROE of 0.2% (sector avg: 22%), net margin of 0.6% (sector avg: 18%). Compare these metrics with sector averages to assess valuation.
Should I buy GDRX stock in 2026?
Our dual AI analysis gives GoodRx Holdings, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GDRX's free cash flow?
GoodRx Holdings, Inc.'s operating cash flow is $11.8M, with capital expenditures of $1.1M. FCF margin is 5.5%.
How does GDRX compare to other Technology stocks?
Vs Technology sector averages: Net margin 0.6% (avg: 18%), ROE 0.2% (avg: 22%), current ratio 1.47 (avg: 2.5).